论文信息 - Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial - 字舞流文

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial

M. Griesshammer | S. Verstovsek | R. Mesa | A. Vannucchi | F. Passamonti | C. Harrison | F. Pane | T. Masszi | S. Durrant | Mark M. Jones | W. Garrett | P. Zachée | J. Kiladjian | U. Pirron | Jingjin Li | Shui He | T. Lawniczek